Literature DB >> 21876344

mRNA expression of bone morphogenetic proteins and their receptors in human renal cell carcinoma.

Dean Markić1, Tanja Ćelić, Antun Gršković, Josip Španjol, Željko Fučkar, Blaženka Grahovac, Gordana Dorđević, Dragica Bobinac.   

Abstract

INTRODUCTION: Bone morphogenetic proteins (BMPs) have been studied in several cancers, but only limited information is available about renal cell carcinomas (RCCs). We determined the expression of mRNA of several BMP ligands and BMP receptors (BMPRs) in healthy kidney tissue and RCCs, and data were compared to clinicopathological parameters.
MATERIAL AND METHODS: Sixty-four samples of RCCs and healthy renal tissues were prospectively examined. The expression of BMP2, BMP4, BMP6, BMP7, BMPRIA, BMPRIB and BMPRII mRNA was determined using semiquantitative reverse transcriptase-polymerase chain reaction.
RESULTS: The expression levels of different BMP ligands and BMPRs were considerably higher in RCCs than in normal kidney tissue. BMP ligands showed elevated expression in clear-cell RCCs, whereas all three BMPRs showed higher expression levels in non-clear-cell RCCs. In clear-cell RCCs, the expression levels of BMP2 progressively increased and expression levels of BMP6, BMP7 and BMPRIB were lost with higher tumor stage.
CONCLUSIONS: All BMPs and their receptors have stronger expression levels in RCC. The expression level of BMP2 is strongly elevated in kidney cancer.
Copyright © 2011 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21876344     DOI: 10.1159/000330797

Source DB:  PubMed          Journal:  Urol Int        ISSN: 0042-1138            Impact factor:   2.089


  3 in total

1.  Upregulation of bone morphogenetic protein 4 is associated with poor prognosis in patients with hepatocellular carcinoma.

Authors:  Xiaodong Guo; Lu Xiong; Lin Zou; Jingmin Zhao
Journal:  Pathol Oncol Res       Date:  2012-02-15       Impact factor: 3.201

2.  Inactivation of bone morphogenetic protein 2 may predict clinical outcome and poor overall survival for renal cell carcinoma through epigenetic pathways.

Authors:  Yozo Mitsui; Hiroshi Hirata; Naoko Arichi; Miho Hiraki; Hiroaki Yasumoto; Inik Chang; Shinichiro Fukuhara; Soichiro Yamamura; Varahram Shahryari; Guoren Deng; Sharanjot Saini; Shahana Majid; Rajvir Dahiya; Yuichiro Tanaka; Hiroaki Shiina
Journal:  Oncotarget       Date:  2015-04-20

3.  Immunogenomic Analyses of the Prognostic Predictive Model for Patients With Renal Cancer.

Authors:  Tao Feng; Jiahui Zhao; Dechao Wei; Pengju Guo; Xiaobing Yang; Qiankun Li; Zhou Fang; Ziheng Wei; Mingchuan Li; Yongguang Jiang; Yong Luo
Journal:  Front Immunol       Date:  2021-10-12       Impact factor: 7.561

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.